A naukri.com initiative
HinduBusinessLine
1d
222
Image Credit: HinduBusinessLine
A new era of diabetes treatment meets old barriers
- Affordable access to more effective diabetes treatment is hindered in low- and middle-income countries by high prices resulting from patent barriers.
- The World Health Organization is considering adding GLP-1 RAs to its Essential Medicines List to encourage procurement and affordability.
- Generic competition could lower the price of semaglutide from $100–300 to under $6 per month.
- Pharmaceutical companies extend monopolies through tactics like evergreening, hindering affordability.
- Novo Nordisk and Lilly hold multiple patents on diabetes drugs, despite the core compound patents expiring soon.
- The clash between patent monopolies and generic manufacturers, like in the Novo Nordisk vs. Dr Reddy's Laboratories case, impacts drug affordability.
- A ruling in favor of generic manufacturers could lead to earlier availability of generic semaglutide and price reductions.
- The outcome of legal battles in India will influence access to diabetes medication in LMICs.
- The court decisions will determine whether affordable access to diabetes treatment is prioritized over patent enforcement.
- The results could impact the timely access to crucial diabetes medications for patients in resource-constrained countries.
Read Full Article
13 Likes
For uninterrupted reading, download the app